ADISCTI (Adis Clinical Trials Insight)

Subject Coverage

- Drugs and drug therapy
- Adverse drug reactions
- Pharmacoeconomics

File Type

Bibliographic, Full text

Features

Thesaurus	None				
Alerts (SDIs)	Weekly				
CAS Registry Number® Identifiers	☐	Page Images	☐	STN® AnaVist™	☐
Keep & Share	☐	SLART	☑	STN Easy®	☐
Learning Database	☐	Structures	☐		

Record Content

- Bibliographic and indexing information
- Summaries contain side effects tables, ADIS comments, global study outcomes, purpose of the paper, author comments, drug tables listing dosage information, results tables.

File Size

More than 175,600 records (08/19)

Coverage

1998-present, from more than 1,700 medical and biomedical publications.

Updates

Weekly

Language

English

Database Producer

Springer International Publishing AG
Copyright Holder

Contact Springer Online Services support desk:
Email: onlineservice@springer.com
Phone: +49 6221 345 4303 (Europe/Asia/Africa)
+1 800 777 4643 (North & South America)

Sources	Adis Clinical Trials Insight
User Aids	• Online Helps (HELP DIRECTORY lists all help messages available) • STNGUIDE
Clusters	• ADISBASES • ALLBIB • AUTHORS • BIOSCIENCE • CORPSOURCE • FULLTEXT • HEALTH • MEDICINE • PHARMACOLOGY • TOXICOLOGY STN Database Clusters information (PDF).
Pricing	Enter HELP COST at an arrow prompt (=>).

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*).

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the title (TI), controlled term (CT), text (TX), and evaluation (EVAL) fields)	None (or /BI)	S PHARMACOKINETICS S QUALITY OF LIFE S RESIST? (L) NEGATIVE S VACCINE# (S) USE S PATIENT-CONTROLLED S ?DIABET(L)?THERAP?	CT, EVAL, TI, TX
Accession Number	/AN	S 2006:1005/AN	AN
ADIS Last Update Date **(2)**	/DUP	S 20051004/DUP	DUP
ADIS Record Creation Date **(2)**	/DED	S 20051004/DED	DED
Author	/AU	S JENSEN P?/AU S JENSEN, P?/AU	AU
Controlled Term	/CT	S THERAPEUTIC EQUIVALENCE/CT S CORONARY SPASM, TREATMENT/CT	CT
Controlled Word	/CW	S (ACICLOVIR (L) ACTIVITY)/CW S (INHIBITORS (S) ANTIMICROBIAL)/CW	CT
Corporate Source (organization name and location) **(1)**	/CS	S (VETERANS AFFAIRS AND ALABAMA)/CS	CS
Document Number	/DN	S 801032402/DN	DN
Document Type (text)	/DT (or /TC)	S BEST EVIDENCE/DT	DT
Entry Date **(2)**	/ED	S L1 AND ED>=20051100	ED
Evaluation **(3,4)**	/EVAL	S CONTROLS/EVAL S MEDIA RELEASE/EVAL	EVAL
Field Availability	/FA	S L3 AND SIDE/FA	Not displayed
International Standard (Document) Number	/ISN	S 8750-2836/ISN	ISN, SO
Journal Title (contains full and abbreviated journal titles)	/JT	S REGION ANESTH/JT S REGIONAL ANESTHESIA/JT	JT, JTA, JTF, SO
Language (code and text)	/LA	S L2 AND ENGLISH/LA S L2 AND EN/LA	LA
Number of Patients **(2,3)**	/PNO	S PNO<=100	PNO
Ongoing Trial Comment	/OT	S TRANSDERMAL?/OT	OT
Other Source	/OS	S 2006000118/OS S ADISINSIGHT/OS	OS
Publication Date **(2)**	/PD	S JUN 1-30 2005/PD	PD, SO
Publication Year **(2)**	/PY	S 2004/PY	PY, SO
Reference **(1)**	/RE	S EPILEPSY DISORDERS/RE	RE
Source (contains journal title, publication date, ISSN, and collation information (volume, issue, and page numbers))	/SO	S (BIOLO? AND BULL? AND VOL 20)/SO	SO
Title *	/TI	S (VITRO AND ACTIVITY)/TI S ?MALARIA?/TI S (KETOLIDE (S) ANTIMICROBIAL)/TI	TI
Update Date **(2)**	/UP	S L7 AND 20021100-20021200/UP	ED
Word Count **(2,3)**	/WC	S L1 AND WC<200	WC

(1) Implied (S) proximity is available in this field.
(2) Numeric search field that may be searched using numeric operators or ranges.
(3) This field is available only in the SUMMARY file segment.
(4) See HELP SCORE for more information.
(5) This score is only available in selected records published in November 2010 and earlier.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Format	Content	Examples
AN **(1)**	Accession Number	D L4 1-4 AN
AU	Author	D AU CS
CS	Corporate Source	D CS 1,3-5
CT **(1)**	Controlled Term (Drug Descriptors, Disease Descriptors, and Other Descriptors)	D CT 5-10
DED	ADIS Record Creation Date	D DED
DN	Document Number	D 1-3,7,8 DN
DT (TC)	Document Type	D DT
DUP	ADIS Last Update Date	D DUP
ED	Entry Date	D ED
EVAL **(2)**	Evaluation (Positive Features, Negative Features, Adis Comment, and Adis Evaluation)	D EVAL 1 5
ISN	International Standard (Document) Number	D ISN
JT **(3)**	Journal Title, Full and Abbreviated	D JT
JTA **(3)**	Journal Title, Abbreviated	D JTA 2
JTF **(3)**	Journal Title, Full	D JTf
LA	Language	D LA
OS	Other Source	D OS
OT	Ongoing Trial Comment	OT
PD **(3)**	Publication Date	D PD
PNO **(1,2)**	Number of Patients	D PNO
PY **(3)**	Publication Year	D PY
RE	Reference	D RE
SO	Source	D SO
TI **(1)**	Title	D TI
TX **(2)**	Text (Global Study Outcome (Efficacy, Tolerability, Pharmacoeconomics), Study Message (Efficacy, Tolerability), Results Highlights (Efficacy, Tolerability), Purpose, Author Comments, Study Details (Design, Control, Phase, Methodology, EndPoints, Companies) Subject Details (Type, No., Age, Sex, Location, Disease, Characteristics), Drug, Drug Table (Drug/Treatment, Dose, Route, Frequency, Duration), Results (Results Table), Case Details (Toxicity, Dechallenge, Outcome, Claimed Association, Key Details), and Age Key)	D TX
UP	Update Date	D UP
WC **(1,2)**	Word Count	D WC
ALL	AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED, EVAL, TX, PNO, CT	D ALL
BIB	AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED	D 2 L5 BIB
CBIB	BIB in compressed format	D CBIB

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
DALL IALL IBIB IND **(1)** SCAN **(1,4)** TEXT **(2)** TRIAL (TRI, SAM) **(1)**	ALL, delimited for post processing ALL, indented with text labels BIB, indented with text labels PNO, CT TI, PNO, CT (random display, no answer numbers) EVAL, TX, PNO TI, PNO, CT	D DALL D IALL D IBIB D IND D SCAN D TEXT D TRIAL TOTAL
HIT KWIC OCC **(1)**	Fields containing hit terms Hit terms with 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they occur	D HIT D KWIC NOH D OCC

(1) No online display fee for this format.
(2) This field is available only in the SUMMARY file segment.
(3) Custom display format only.
(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Accession Number	AN	Y	N
ADIS Last Record Update	DUP	Y	Y
ADIS Record Creation Date	DED	Y	Y
Author	AU	Y	Y
Citation	CIT	Y **(2,3)**	N
Controlled Term	CT	Y	N
Corporate Source	CS	Y	Y
Document Number	DN	Y	Y
Document Type	DT	Y	Y
Entry date	ED	Y	Y
Evaluation **(4)**	EVAL	Y	N
File Segment	FS	Y	Y
International Standard (Document) Number	ISN	Y	Y
Journal Title	JT	Y **(5)**	Y
Journal Title, Abbreviated	JTA	Y **(6)**	Y
Journal Title, Full	JTF	Y **(6)**	Y
Language	LA	Y	Y
Number of Patients **(4)**	PNO	Y	Y
Occurrence Count of Hit Terms	OCC	N	Y
Ongoing Trial Comment	OT	Y	N
Other Source	OS	Y	N

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Publication Date	PD	Y	Y
Publication Year	PY	Y	Y
Reference	RE	Y	Y
Text **(4)**	TX	Y **(7)**	N
Title	TI	Y (default)	Y
Treatment Code	TC	Y	Y
Update Date	UP	Y	Y
Word Count **(4)**	WC	N	Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CT.
(2) SELECT HIT and ANALYZE HIT are not valid with this field.
(3) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms created by SELECT.
(4) This field is available only in the SUMMARY file segment.
(5) Selects or analyzes full and abbreviated journal titles with /JT appended to the terms created by SELECT.
(6) Appends /JT to the terms created by SELECT.
(7) Appends /BI to the terms created by SELECT.

Full-Text Browsing

User Request	Example	System Response
DISPLAY BROWSE	=> DISPLAY BROWSE ENTER (L1) OR L#:. ENTER (DIS), ANSWER NUMBERS, OR END:	NOVICE version
D BRO	=> D BRO L1 :	EXPERT version
Answer number(s)	:1-3	display answers 1, 2, and 3 in default format
Answer number(s) and format	:4 HIT	display answer 4 in HIT format
Format only	:TI TX	display title and text of last answer displayed
Change default format	:*KWIC	change default to KWIC no answer displayed
Forward n fields	:F3	move forward 3 fields
Backward n fields	:B1	move backward 1 field
Search forward for character string	:S BONE MARROW	search forward within record for 'bone marrow'
Search backward for character string	:S- NAUSEA	search backward within record for 'nausea'
End DISPLAY BROWSE	:END =>	exit DISPLAY BROWSE and return to => prompt

Sample Records

DISPLAY IALL

```
ACCESSION NUMBER:        2006:18471   ADISCTI
DOCUMENT NUMBER:         700009023
TITLE:                   ADIS TITLE: Effectiveness of an NK1 Antagonist in
                         PTSD.
DOCUMENT TYPE:           Ongoing Trial
ADIS REC. CREATED:       26 Nov 2005
ADIS LAST UPDATE:        4 Mar 2014
REFERENCE:               Anxiety Disorders; Mental Disorders
                         1.) ClinicalTrials.gov: US National Institutes of
                         Health
LANGUAGE:                English
WORD COUNT:              283
OTHER SOURCE:            ADISINSIGHT 1998005744
ENTRY DATE:              Entered STN: 12 Jun 2006
                         Last Updated on STN: 7 Mar 2014
ONGOING TRIAL COMNT:     Ongoing Trial Comment: This trial is entitled
                         "Effectiveness of an NK1 Antagonist [vofopitant] in
                         PTSD [post-traumatic stress disorder]". The primary
                         outcome is the change in 17-item total severity
                         Clinician Administered PTSD Scale.

TEXT - Subject Details:
Planned No: 47
No: 64
Location: USA
Disease: Post-traumatic-stress-disorders
Patient Inclusion: Aged 18-65 years; diagnosis of post-traumatic  stress
disorder for greater than or equal to 3 months; negative urine  toxicology
test; females willing to use an effective form of birth  control throughout the
study.
 Patient Exclusion: Current diagnosis of schizophrenia or other  psychotic
disorder, current diagnosis of bipolar disorder or other  psychiatric disorder
except for depression secondary to post-traumatic  stress disorder,
participation in a clinical trial of a new drug during  the previous 4 months
or any other trial during the previous 3 months,  current evidence or history
of serious unstable medical illness or  organic brain impairment, serious
suicidal or homicidal risk, substance  abuse within the last 90 days, use of
effective psychiatric medications  in the 2 weeks prior to screening or
***fluoxetine***   in last 5 weeks,  consumption of more than 4 drinks/day per
week if male or of more than 3  drinks/day per week if female, donation of
blood within the previous  month or intent to donate blood within one month of
completing the study,  previous treatment with an NK1 antagonist.
TEXT - Age Key: adult, elderly
TEXT - Study Details:
Status: completed
Actual Start: August 2005
Planned Finish: November 2008
Actual Finish: November 2008
Design: double-blind, parallel, prospective, randomised
Phase: II
Endpoints: Assessment scale scores
Biomarker levels (CSF levels of norepinephrine (NE) and NE metabolites.)
Brain volume (Hippocampal volume.)
clinical Global Impressions scale
Clinical response rate
Improvement in symptoms
Magnetic resonance imaging outcomes, Clinician Administered Post-Traumatic
Stress Disorder Scale
Study Center: Baylor School of Medicine, Mount Sinai School of Medicine, Emory
University, National Institute of Mental Health
Companies: GlaxoSmithKline
```

ADISCTI

ID: 700009023 (Clinical Trials Insight)
NCT00211861 (ClinicalTrials.gov: US National Institutes of Health)
U19MH069056()

NO. OF PATIENTS: 64

CONTROLLED TERM: Drug Descriptors: Vofopitant
CONTROLLED TERM: Disease Descriptors: Post traumatic stress disorders, treatment

In North America
CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:
Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)
Fax: 614-447-3751
Email: help@cas.org
Internet: www.cas.org

In Europe
FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax: +49-7247-808-259
Email: helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan
JAICI (Japan Association for
International Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Fax: +81-3-5978-3600
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp